SLC12A5 and epilepsy: The mechanism by which KD acts effectively in epilepsy is not clearly understood; however, the fact that KD has beneficial effects in diseases in which the KCC2 cotransporter is affected has led to the proposal that modifications in the expression of the cation-chloride cotransporter KCC2 could be at least in part the mechanism of action of this diet in epilepsy (Wang et al., 2016; Granados-Rojas et al., 2020; Murakami and Tognini, 2022).